INDGN Indegene Q1 FY26 results (Apr–Jun 2025) and concall
Indegene's corporate update centered on the strategic acquisition of BioPharm to bolster its Brand Activation segment and omnichannel execution capabilities. The deal, valued at $104 million, integrates high-margin specialized marketing services and a massive proprietary HCP data engine. Management is focused on leveraging BioPharm's U.S. presence to cross-sell into Indegene's large pharma client base while targeting margin expansion through offshoring and data cost synergies.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 282 | 287 | 267 | 256 |
| EBITDA | 46 | 52 | 40 | 37 |
| Net profit | 45 | 50 | 54 | 45 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
